Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: A pilot study in Taiwan

Cheng Jeng Tai, Jin Hwang Liu, Wei Shon Chen, Jen Kou Lin, Wei Shu Wang, Chueh Chuan Yen, Tzeon Jye Chiou, Po Min Chen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Irinotecan (CPT11) has established activity against advanced colorectal cancer without cross-resistance with 5-fluorouracil + leucovorin-based therapy. We conducted this pilot study to evaluate the efficacy and tolerance of combination treatment with irinotecan and 5-fluorouracil (5-FU) for patients in whom combination treatment with oxaliplatin with 5-FU + leucovorin has failed. Methods: Patients were e nrolled in this study after oxaliplatin treatment had failed. The treatment protocol consisted of CPT11 (180 mg/m2 for 90 min) on day 1 and a 2 h infusion of 200 mg/m2 leucovorin followed by 400 mg/m2 5-FU as an intravenous bolus injection plus a 22 h continuous infusion of 600 mg/m2 5-FU. This regimen was repeated for two consecutive days every 2 weeks. Results: A total of 18 patients were eligible for this study and in total 144 cycles of therapy (median eight cycles) were given to these patients. Four patients (22.2% 95% CI: 8-36.4%) achieved an objective response of partial remission (PR) and an additional seven obtained stable disease (SD) status or minor response. The median duration of response was 8 months and 14 patients were alive at the end of the study. Hematological toxicity (neutropenia) was the most common serious side effect (29.2%), followed by gastrointestinal effects (diarrhea, 28.5%). Grade II-III diarrhea was experienced for at least one cycle by each patient. Conclusions: The results of treatment for patients after oxaliplatin failure are encouraging and this treatment protocol is also well tolerated by previously heavily treated patients.

Original languageEnglish
Pages (from-to)136-140
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume33
Issue number3
DOIs
Publication statusPublished - Mar 1 2003
Externally publishedYes

Fingerprint

oxaliplatin
irinotecan
Salvage Therapy
Leucovorin
Taiwan
Fluorouracil
Colorectal Neoplasms
Clinical Protocols
Diarrhea
Therapeutics

Keywords

  • Chemotherapy
  • Irinotecan
  • Metastatic colorectal cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology

Cite this

Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV : A pilot study in Taiwan. / Tai, Cheng Jeng; Liu, Jin Hwang; Chen, Wei Shon; Lin, Jen Kou; Wang, Wei Shu; Yen, Chueh Chuan; Chiou, Tzeon Jye; Chen, Po Min.

In: Japanese Journal of Clinical Oncology, Vol. 33, No. 3, 01.03.2003, p. 136-140.

Research output: Contribution to journalArticle

@article{1278dceeea1c4fe5a9af32e52ef50e95,
title = "Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: A pilot study in Taiwan",
abstract = "Irinotecan (CPT11) has established activity against advanced colorectal cancer without cross-resistance with 5-fluorouracil + leucovorin-based therapy. We conducted this pilot study to evaluate the efficacy and tolerance of combination treatment with irinotecan and 5-fluorouracil (5-FU) for patients in whom combination treatment with oxaliplatin with 5-FU + leucovorin has failed. Methods: Patients were e nrolled in this study after oxaliplatin treatment had failed. The treatment protocol consisted of CPT11 (180 mg/m2 for 90 min) on day 1 and a 2 h infusion of 200 mg/m2 leucovorin followed by 400 mg/m2 5-FU as an intravenous bolus injection plus a 22 h continuous infusion of 600 mg/m2 5-FU. This regimen was repeated for two consecutive days every 2 weeks. Results: A total of 18 patients were eligible for this study and in total 144 cycles of therapy (median eight cycles) were given to these patients. Four patients (22.2{\%} 95{\%} CI: 8-36.4{\%}) achieved an objective response of partial remission (PR) and an additional seven obtained stable disease (SD) status or minor response. The median duration of response was 8 months and 14 patients were alive at the end of the study. Hematological toxicity (neutropenia) was the most common serious side effect (29.2{\%}), followed by gastrointestinal effects (diarrhea, 28.5{\%}). Grade II-III diarrhea was experienced for at least one cycle by each patient. Conclusions: The results of treatment for patients after oxaliplatin failure are encouraging and this treatment protocol is also well tolerated by previously heavily treated patients.",
keywords = "Chemotherapy, Irinotecan, Metastatic colorectal cancer, Oxaliplatin",
author = "Tai, {Cheng Jeng} and Liu, {Jin Hwang} and Chen, {Wei Shon} and Lin, {Jen Kou} and Wang, {Wei Shu} and Yen, {Chueh Chuan} and Chiou, {Tzeon Jye} and Chen, {Po Min}",
year = "2003",
month = "3",
day = "1",
doi = "10.1093/jjco/hyg023",
language = "English",
volume = "33",
pages = "136--140",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV

T2 - A pilot study in Taiwan

AU - Tai, Cheng Jeng

AU - Liu, Jin Hwang

AU - Chen, Wei Shon

AU - Lin, Jen Kou

AU - Wang, Wei Shu

AU - Yen, Chueh Chuan

AU - Chiou, Tzeon Jye

AU - Chen, Po Min

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Irinotecan (CPT11) has established activity against advanced colorectal cancer without cross-resistance with 5-fluorouracil + leucovorin-based therapy. We conducted this pilot study to evaluate the efficacy and tolerance of combination treatment with irinotecan and 5-fluorouracil (5-FU) for patients in whom combination treatment with oxaliplatin with 5-FU + leucovorin has failed. Methods: Patients were e nrolled in this study after oxaliplatin treatment had failed. The treatment protocol consisted of CPT11 (180 mg/m2 for 90 min) on day 1 and a 2 h infusion of 200 mg/m2 leucovorin followed by 400 mg/m2 5-FU as an intravenous bolus injection plus a 22 h continuous infusion of 600 mg/m2 5-FU. This regimen was repeated for two consecutive days every 2 weeks. Results: A total of 18 patients were eligible for this study and in total 144 cycles of therapy (median eight cycles) were given to these patients. Four patients (22.2% 95% CI: 8-36.4%) achieved an objective response of partial remission (PR) and an additional seven obtained stable disease (SD) status or minor response. The median duration of response was 8 months and 14 patients were alive at the end of the study. Hematological toxicity (neutropenia) was the most common serious side effect (29.2%), followed by gastrointestinal effects (diarrhea, 28.5%). Grade II-III diarrhea was experienced for at least one cycle by each patient. Conclusions: The results of treatment for patients after oxaliplatin failure are encouraging and this treatment protocol is also well tolerated by previously heavily treated patients.

AB - Irinotecan (CPT11) has established activity against advanced colorectal cancer without cross-resistance with 5-fluorouracil + leucovorin-based therapy. We conducted this pilot study to evaluate the efficacy and tolerance of combination treatment with irinotecan and 5-fluorouracil (5-FU) for patients in whom combination treatment with oxaliplatin with 5-FU + leucovorin has failed. Methods: Patients were e nrolled in this study after oxaliplatin treatment had failed. The treatment protocol consisted of CPT11 (180 mg/m2 for 90 min) on day 1 and a 2 h infusion of 200 mg/m2 leucovorin followed by 400 mg/m2 5-FU as an intravenous bolus injection plus a 22 h continuous infusion of 600 mg/m2 5-FU. This regimen was repeated for two consecutive days every 2 weeks. Results: A total of 18 patients were eligible for this study and in total 144 cycles of therapy (median eight cycles) were given to these patients. Four patients (22.2% 95% CI: 8-36.4%) achieved an objective response of partial remission (PR) and an additional seven obtained stable disease (SD) status or minor response. The median duration of response was 8 months and 14 patients were alive at the end of the study. Hematological toxicity (neutropenia) was the most common serious side effect (29.2%), followed by gastrointestinal effects (diarrhea, 28.5%). Grade II-III diarrhea was experienced for at least one cycle by each patient. Conclusions: The results of treatment for patients after oxaliplatin failure are encouraging and this treatment protocol is also well tolerated by previously heavily treated patients.

KW - Chemotherapy

KW - Irinotecan

KW - Metastatic colorectal cancer

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=0038519895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038519895&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyg023

DO - 10.1093/jjco/hyg023

M3 - Article

C2 - 12672791

AN - SCOPUS:0038519895

VL - 33

SP - 136

EP - 140

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 3

ER -